Meina Ye

Dr. Meina Ye


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2018 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
YZYuzhu Zhang
Yuzhu Zhang
JWJingjing Wu
Jingjing Wu
MYMeina Ye
Meina Ye
BWBing Wang
Bing Wang
JSJiayu Sheng
Jiayu Sheng
HCHongfeng Chen
Hongfeng Chen
Platinum-based drugs are used extensively in neoadjuvant chemotherapy for triple-negative breast cancer (TNBC), but their use can be limited by resistance. In this study, we established cisplatin (DDP) resistant TNBC cells to investigate the potential relationship among ETS1, IKKα/NF-κB and resistance. The sensitivity was evaluated by MTT, apoptosis analysis. The intracellular DDP concentration difference was tested by inductively coupled plasma mass spectrometry (ICP-MS) method. Molecular pathological mechanism of DDP resistance was explored by microarray analysis and PPI network analysis. The ETS1, NF-κB signaling change were assessed by western blot and q-PCR in vitro and vivo. The existing binds between ETS1 and the core IKKα promoter were found by luciferase assay and chromatin immunoprecipitation technique (ChIP). MDA-MB-231/DDP (231/DDP) cell had a higher IC50 value of cisplatin, lower intracellular DDP concentration, and lower apoptosis ratio than MDA-MB-231 (231/wt) cell line treated with DDP. Increased ABC transporters were induced by the activation of NF-κB pathway in 231/DDP cells. ETS1, RPL6, RBBP8, BIRC2, PIK3A and RARS were six important genes for DDP-resistance based on PPI network and expression validation. Protein expression of ETS1 and IKKα were significantly up-regulated in 231/DDP cells. However, inhibition of ETS1 expression enhances chemo-sensitivity to DDP and reversed the activation of NF-κB pathway in 231/DDP cells and subcutaneous transplantation tumor in vivo. Moreover, there is existing binds between ETS1 and the core IKKα promoter though luciferase assay and ChIP. This study enables us to understand the functions of ETS1 in TNBC chemotherapy and suggests that ETS1 could be used as a novel marker of poor response to DDP and a potential therapeutic target for TNBC chemotherapy.

2 April 2025 in Translational Oncology
Verified
Journal Article
Open access
MCMeiling Chu
Meiling Chu
YZYan Zhang
Yan Zhang
MYMeina Ye
Meina Ye
YYYu-lian Yin
Yu-lian Yin
HCHong-feng Chen
Hong-feng Chen
Aromatase inhibitors (AIs) are the main drugs used in the endocrine therapy of breast cancer. Given the continuous reduction in their estrogen levels, the quality of life and medication compliance of patients with osteopenia and osteoporosis, also called aromatase inhibitor-associated bone loss (AIBL), are seriously affected. Yi Shen Tiao Gan decoction (YSTG) is a traditional Chinese medicine prescription that is widely used in China to treat AIBL. Clinical studies have shown that YSTG can effectively decelerate AIBL. However, the molecular mechanisms underlying the effects of YSTG on AIBL remain unclear. In contrast to previous studies on the mechanism of AIBL, which focused on the relationship between estrogen and osteoclasts, this study adopts a novel perspective by focusing on H-type blood vessels and Slit guidance ligand 3 (SLIT3). H-type vessels, a recently identified subtype of capillaries, are predominantly located in the epiphysis and endosteum of long bones. These vessels play a crucial role in mediating the coupling of angiogenesis and osteogenesis within the bone microenvironment, with their abundance serving as a sensitive indicator of bone mass. Notably, SLIT3, a proangiogenic factor secreted by osteoblasts, is actively involved in the regulation of H-type vessel formation and bone formation processes. Here, we used the inoculation and resection of breast cancer xenografts, bilateral ovaritectomy (OVX), and gavage of letrozole (Femara) to construct a suitable AIBL animal model, which was verified by ELISA, microcomputed tomography (micro-CT), hematoxylin and eosin staining, and OCN and tartrate-resistant acid phosphatase (TRAP) immunohistochemical staining. H-type vessels were used as the entry point to study the mechanism of AIBL on the basis of the AIBL animal model. Among mice, the nude mice in the mastectomy (MX)+OVX+Le group showed the most severe bone loss after breast cancer cell implantation and resection, OVX, and Le gavage. Therefore, this group was suitable as an animal model of breast cancer AIBL than other groups. The animal experiment on the mechanism of YSTG in improving bone loss found that YSTG treatment significantly reduced the contents of C-terminal telopeptide of type I collagen, procollagen type I N-terminal propeptide, and growth hormone and increased those of serum estradiol and SLIT3. Micro-CT quantitative detection showed that after YSTG treatment, bone BMD, BV:TV, and Tb.N increased. The HE staining of bone tissue revealed that the thickness and number of trabecular bone and the number of cells in the cartilage layer of the femur remarkably increased after YSTG treatment. YSTG reduced TRAP content near the growth plate of the femoral metaphysis. YSTG significantly increased the OCN content at the margin of the trabecular bone in the metaphysis of the femur. Immunofluorescence results confirmed that YSTG could increase the amount of H-type vascular cells in bone. WB analysis confirmed that YSTG could significantly up-regulate the expression of SLIT3 protein in bone tissue. Therefore, YSTG may improve bone loss by up-regulating SLIT3 to induce H-type angiogenesis.

12 March 2025 in Scientific Reports
Verified
Journal Article
Open access
YYYu-lian Yin
Yu-lian Yin
HLHaoxin Le
Haoxin Le
YCYifan Cheng
Yifan Cheng
YZYuanyuan Zhong
Yuanyuan Zhong
YCYiqin Cheng
Yiqin Cheng
HCHongfeng Chen
Hongfeng Chen
Non-puerperal mastitis (NPM) is an umbrella term for non-specific inflammatory mastitis that occurs during the non-puerperal period and has an unclear aetiology. The current study aims to characterize NPM patients and examine the determinants associated with NPM severity. This study analyzed the NPM inpatients admitted to the Department of Breast Surgery, Longhua Hospital Affiliated with the Shanghai University of Traditional Chinese Medicine from 2016 to 2020. We explored NPM patient characteristics through demographics, physical risks, lab tests, and medical history indicators. Multivariable logistic regression was conducted to identify the relationship between the prolactin (PRL) level and NPM severity stratified by breast structure. The majority of NPM inpatients had normal breast structures and were of lower average age than those with congenital nipple deformity (p = 0.002). Significant positive risk (p < 0.001) association between PRL level and NPM severity was observed among NPM inpatients with normal breast structure in both crude and adjusted models (adjusted OR: 2.91; 95%CI:1.88-4.52), with younger age as a protective factor (OR:0.94; 95%CI:0.91-0.97) and smoking history as a risk factor (OR:2.22; 95%CI:1.22-4.05). For NPM patients with nipple deformity, increasing odds of NPM severity regarding higher PRL level was observed while the result is not statistically significant at 0.05 level. (OR: 2.17; 95%CI: 0.94-5.03). The risk of NPM severe episodes is higher among patients with higher PRL levels, of which the association is stronger for NPM patients with normal breast structure, implying different pathogenesis between NPM patients with varied breast anatomy. Disagreement of the interaction effect testification indicates an improvement window for the current study.Trial registration: ChiCTR2000035929. Registered 20 August 2020(retrospectively registered).

28 July 2025 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
PDF file
STSiyuan Tu
Siyuan Tu
YYYulian Yin
Yulian Yin
LMLina Ma
Lina Ma
HCHongfeng Chen
Hongfeng Chen
MYMeina Ye
Meina Ye
Background: Non-puerperal mastitis (NPM) arises from heterogeneous factors ranging from autoimmune dysregulation to occult infections. To establish a diagnosis, biopsy is reliable but invasive. Imaging exhibits a limited specificity and may cause diagnostic delays, patient discomfort, and suboptimal management. Inspired by non-invasive tongue diagnosis in traditional Chinese medicine, this study integrated tongue-coating microbiota profiling and AI-quantified tongue image phenotyping to establish an objective, non-invasive diagnostic framework for NPM.Methods: A total of 100 NPM patients from the Breast Surgery Department of Longhua Hospital and 100 healthy volunteers were included. Their clinical characteristics, tongue images, and tongue-coating microbiota data were collected. Features of tongue images (detection, segmentation, and classification) were quantitated and extracted via deep learning. The microbiota composition was assessed using 16S rRNA gene sequencing (V3–V4 region) and bioinformatic pipelines (QIIME2, DADA2). Based on clinical, imaging, and microbial features, three machine learning models—logistic regression (LR), support vector machine (SVM), and gradient boosting decision tree (GBDT)—were trained to distinguish NPM.Results: The GBDT model achieved a superior diagnostic performance (AUROC = 0.98, accuracy = 0.95, and specificity = 0.95), outperforming the LR (AUROC = 0.98, accuracy = 0.95, and specificity = 0.90) and SVM models (AUROC = 0.87, accuracy = 0.80, and specificity = 0.75). Integration of clinical characteristics, tongue image features, and bacterial profiles (at the genus/family level) yielded the highest accuracy, whereas models using a single class of features showed a lower discriminatory ability (AUROC = 0.90–0.91). Key predictors included Campylobacter (12%), waist–hip ratio (11%), and Alloprevotella (6%).Conclusions: Integrating clinical characteristics, tongue image features, and tongue-coating microbiota profiles, the multimodal GBDT model demonstrates a high diagnostic accuracy, supporting its utility for early screening and diagnosis of NPM.

6 September 2024 in Frontiers in Surgery
Verified
Journal Article
Open access
PDF file
ZSZiyue Sun
Ziyue Sun
KLKexin Liu
Kexin Liu
YGYanru Guo
Yanru Guo
NJNanyuan Jiang
Nanyuan Jiang
MYMeina Ye
Meina Ye
Locally advanced breast cancer (LABC) remains a significant clinical challenge, particularly in developing countries. While neoadjuvant systemic therapy (NST) has improved the pathological complete response (pCR) rates, particularly in HER2-positive and triple-negative breast cancer patients, surgical management post-NST continues to evolve. The feasibility of omitting surgery and the increasing consideration of breast-conserving surgery, immediate reconstruction in LABC patients are important areas of exploration. Accurate assessment of tumor response to NST through advanced imaging and minimally invasive biopsies remains pivotal, though challenges persist in reliably predicting pCR. Additionally, axillary lymph node management continues to evolve, with emerging strategies aiming to minimize the extent of surgery in patients who achieve nodal downstaging post-NST. Minimizing axillary lymph node dissection in favor of less invasive approaches is gaining attention, though further evidence is needed to establish its oncological safety. The potential for personalized treatment approaches, reducing surgical morbidity, and improving quality of life are key goals in managing LABC, while maintaining the priority of achieving favorable long-term outcomes.

1 September 2025 in World Journal of Integrated traditional and western Medicine(WJIM)
Verified
Journal Article
Open access
PDF file
STSiyuan Tu
Siyuan Tu
YYYulian Yin
Yulian Yin
JXJiachen Xu
Jiachen Xu
HCHongfeng Chen
Hongfeng Chen
XWXueqing Wu
Xueqing Wu
MYMeina Ye
Meina Ye
In accordance with the Guiding Opinions of the Central Committee of the Communist Party of China and the State Council on Promoting the Inheritance and Innovation of Traditional Chinese Medicine (TCM), the China Association of Chinese Medicine (CACM) organized multidisciplinary symposia on TCM-dominant diseases with the aim of advancing research on clinically dominant diseases in TCM, supporting specialty development, cultivating clinical talent, developing strategic plans for national science, and fostering academic innovation. The 42nd Academic Salon on Clinically Dominant Diseases, which was convened in Shanghai on 24 November 2024, brought together TCM experts, Western medicine experts, and interdisciplinary researchers for in-depth discussions on the current status, strengths, and limitations of and strategies to improve the integrated diagnosis and treatment of plasma cell mastitis (PCM). While consensus had been reached on recommendations for TCM and integrated approaches, detailed research pathways remain to be developed. In this work, we systematically examine the pathogenesis of and clinical management challenges related to PCM. Building on the therapeutic strengths of TCM, we propose five prioritized research domains with corresponding scientific planning: (1) Early identification and intervention strategies for PCM; (2) The optimization of TCM syndrome differentiation systems for PCM; (3) The standardization of efficient evaluation metrics for PCM therapies; (4) Mechanistic studies on the pathogenesis of PCM and TCM therapeutic targets; (5) Prevention protocols and complication management frameworks for PCM. We further delineate recommended research directions, anticipated outcomes, value propositions, and funding priorities. The aim of this research model, which was derived from the PCM-focused academic salon series, is to advance the development of high-quality TCM practices by informing national scientific planning, innovative drug development, research priorities, and the formulation of clinical guidelines.